RecruitingNCT03683251
Extension Study for the Port Delivery System With Ranibizumab (Portal)
PHASE3 · 1,000 planned enrolment
- Countries listed
- 15
- Registry update
- September 28, 2026
immortal.lifeTrial registrations containing the exact intervention label PDS Implant with Ranibizumab 100 mg/mL.
No aliases or equivalent products have been inferred.
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →PHASE3 · 1,000 planned enrolment